Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial

Outcomes were assessed at clinic discharge or 9 months after the initial visit. The primary outcome was a score of 4 or 5 on a 5-point Likert scale assessing global symptom improvement. After treatment, median HADS scores were higher in the standard- care group than in the multi-disciplinary group.

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Liver transplantation did not significantly increase the risk of death in patients with SARS-CoV-2 infection. Increased age and presence of comorbidities were. associated with death. Physical distancing and provision of medical care for patients with liver transplants should be considered.

Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients with NAFLD and constipation. The most common adverse event was diarrhea. No life-threatening events or treatment-related deaths occurred.

Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden

The use of antibiotics in early life has been linked with childhood inflammatory bowel disease (IBD) Data for adults are mixed and smaller investigations did not compare risk among siblings. Findings suggest the need to further emphasise antibiotic stewardship to prevent the rise in dysbiosis-related chronic diseases.

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH. NIS4 algorithm comprised four independent NASH-associated biomarkers.

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9) It's a promising novel therapeutic target in ulcerative colitis and warrants further testing. The study was based on a computer-generated schedule and a centralized interactive voice and web response system.

Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis

Previous estimates of the magnitude of this issue have not accounted for ongoing inflammation as the potential cause. Of 3370 studies identified, 27 were eligible, of which 18 were newly identified. Among 3169 patients with IBD in remission, 32% had IBS-type symptoms. Prevalence was lower when remission was defined by endoscopic assessment or histological assessment.

Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis

Tenofovir disoproxil fumarate and entecavir differ in their association with the risk of hepatocellular carcinoma. Treatment should be guided by patient tolerability and affordability rather than whether one drug is more effective than the other.

Departments

Recent Posts